News stories about Stellar Biotechnologies (NASDAQ:SBOT) have trended somewhat negative recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Stellar Biotechnologies earned a daily sentiment score of -0.02 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 47.735399032603 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of Stellar Biotechnologies (SBOT) traded down $0.04 during mid-day trading on Wednesday, hitting $0.88. 228,100 shares of the stock were exchanged, compared to its average volume of 246,417. Stellar Biotechnologies has a 52 week low of $0.75 and a 52 week high of $2.22. The firm has a market cap of $9.31, a PE ratio of -1.80 and a beta of 1.21.
WARNING: This piece was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.com-unik.info/2018/01/10/stellar-biotechnologies-sbot-getting-somewhat-critical-media-coverage-report-shows.html.
About Stellar Biotechnologies
Stellar Biotechnologies, Inc is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases.
Receive News & Ratings for Stellar Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stellar Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.